Business
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)
As a pioneer of nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ChromaDex aims to raise awareness amongst industry leaders LOS
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":"\nAs a pioneer of nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ChromaDex aims to raise awareness amongst industry leaders\n\n LOS ANGELES--(BUSINESS WIRE)--\nChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CERP™) investigators, will be presenting at several key scientific conferences including the American Society for Nutrition’s (ASN) Nutrition 2022, the International Society of Sports Nutrition (ISSN) annual meeting, and Federation of American Societies for Experimental Biology (FASEB), The NAD+ Metabolism and Signaling Conference. CERP™ is a pioneering program in nicotinamide adenine dinucleotide (NAD+) research and healthy aging and most recently celebrated over 250 material transfer agreements with over 235 independent scientists, doctors, and investigators across 182 institutions and 33 countries. Many of the agreements were developed to study Niagen®, ChromaDex’s proprietary nicotinamide riboside (NR) ingredient, an efficient precursor for the essential cellular coenzyme, NAD+. ChromaDex aims to raise awareness of this research at ASN, ISSN and FASEB.\n\nBelow is an overview of how ChromaDex will be participating in each event.\n\nAmerican Society for Nutrition, Nutrition 2022, June 14-16, 2022 (Virtual):\n\nChromaDex and co-sponsor Balchem are sponsoring the Satellite Program, Exploring the Role of Selected Vitamins and Essential Nutrients in Cognition: Impact of Supplementation on Neurodegeneration, which takes place today on June 15 from 12:00-1:30pm EDT. The discussion will feature two CERP™ investigators, Dr. Charalampos Tzoulis (Clinical Neurologist and Professor of Neurology & Neurogenetics, Haukeland University Hospital, University of Bergen, Norway), and Dr. Vilhelm Bohr (Retired Laboratory Chief, Laboratory of Molecular Gerontology, National Institutes on Aging, National Institutes of Health in Baltimore, Maryland) alongside Dr. Jim Ray (Executive Director Neuroscience, The Neurodegeneration Consortium, MD Anderson Cancer Center in Houston, Texas).\n\nIn addition, three ChromaDex employees will be presenting at the conference: Rebecca Idoine, CERP™ Specialist at ChromaDex, will present in the session Impact of Boosting NAD+ on Immune Function: Results from Nicotinamide Riboside Preclini...